OrganoTherapeutics starts a collaboration with StressMarq Biosciences
- OrganoTherapeutics GmbH has signed a collaboration agreement with StressMarq Biosciences INC.
- This collaboration with focus on advancing research on Parkinson’s Disease alpha-synuclein pathology in midbrain organoids.
The Luxembourg based biotech OrganoTherapeutics uses a patient-specific brain organoid model to research Parkinson’s Disease pathology in vitro and develop new therapeutics against the disease progression. In October 2023, OrganoTherapeutics, signed a collaboration agreement with the bioreagents company StressMarq Biosciences. This collaboration will focus on researching alpha-synuclein – a crucial protein for Parkinson’s Disease development – in organoids.
The OrganoTherapeutics’ research project leader , Dr. Gemma Gómez Giró mentions “I am excited to start this collaboration with Stressmarq to establish an RT-QuIC assay for alpha-synuclein amplification in our organoid models. This assay has become very relevant for diagnostic purposes in Parkinson's disease patients, however, they have never been tested in organoids. We believe that the high sensitivity of the assay will allow us to detect alpha-synuclein pathological aggregates in our samples, and will become a primary readout in our drug screenings. The products and expertise from Stressmarq will be crucial to guide us into succeeding when implementing this assay”.
About StressMarq Biosciences:
StressMarq Biosciences INC is a Canada-based company that produces bioreagents for life sciences and drug discovery research. Established in 2007, it is a market leader in the development of products targeting proteins in fibril and oligomer form to research neurodegeneration.
For more information visit: https://www.stressmarq.com
About OrganoTherapeutics:
OrganoTherapeutics was founded in July 2019 as spin-off biotech from the University of Luxembourg / Luxembourg Centre for Systems Biomedicine. Through the use of a proprietary human-specific, personalized, 3D in vitro model, the midbrain organoids they conduct research studies for the discovery and development of effective drug candidates, which target neurodegeneration in Parkinson`s disease (PD) patients. OrganoTherapeutics focuses on deep phenotyping and phenotype-based drug screening, as well as artificial intelligence-assisted analysis.